Profile data is unavailable for this security.
About the company
Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company’s anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are 100% water soluble at all pH levels in their liquid form.
- Revenue in AUD (TTM)6.81m
- Net income in AUD-11.32m
- Incorporated2007
- Employees--
- LocationRecce Pharmaceuticals LtdLevel 23180 George St, Salesforce TowerSYDNEY 2000AustraliaAUS
- Phone+61 29256-2505
- Fax+61 28075-4584
- Websitehttps://www.recce.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitura Health Ltd | 119.67m | 9.40m | 63.35m | 121.00 | 6.68 | 1.61 | 16.75 | 0.5293 | 0.0165 | 0.0165 | 0.2099 | 0.0681 | 1.98 | 11.22 | 10.51 | 989,034.20 | 15.25 | 15.29 | 22.30 | 21.06 | 31.23 | -- | 7.70 | 6.92 | 1.18 | 5,598.19 | 0.2359 | -- | 75.16 | -- | 128.31 | 146.95 | 54.86 | -- |
| Biome Australia Ltd | 10.24m | -2.86m | 65.98m | 30.00 | -- | 30.60 | -- | 6.44 | -0.0141 | -0.0141 | 0.0506 | 0.0101 | 1.37 | 1.93 | 6.04 | 341,434.70 | -38.27 | -- | -74.60 | -- | 61.29 | -- | -27.97 | -- | 0.9514 | -15.92 | 0.4032 | -- | 73.58 | -- | 32.20 | -- | -- | -- |
| Percheron Therapeutics Ltd | 624.51k | -10.85m | 67.62m | 8.00 | -- | 4.11 | -- | 108.27 | -0.0157 | -0.0157 | 0.0009 | 0.0182 | 0.0328 | -- | 0.3224 | -- | -56.94 | -72.09 | -66.58 | -81.73 | -- | -- | -1,737.37 | -6,558.90 | -- | -- | 0.001 | -- | 1,026.16 | 72.03 | -95.81 | -- | -- | -- |
| Actinogen Medical Ltd | 337.51k | -14.87m | 69.73m | -- | -- | 5.08 | -- | 206.61 | -0.0073 | -0.0073 | 0.0002 | 0.0051 | 0.0211 | -- | 0.7341 | -- | -92.99 | -45.55 | -105.88 | -48.24 | -- | -- | -4,405.86 | -5,369.76 | -- | -294.93 | 0.0037 | -- | 792.74 | 31.88 | -13.21 | -- | 166.95 | -- |
| PharmAust Limited | 1.85m | -7.79m | 73.24m | 52.00 | -- | 9.27 | -- | 39.57 | -0.0236 | -0.0201 | 0.0055 | 0.02 | 0.1977 | -- | 6.71 | -- | -83.26 | -25.56 | -96.46 | -28.78 | 20.06 | 90.73 | -421.04 | -59.16 | -- | -104.65 | 0.00 | -- | -13.53 | 3.42 | -263.63 | -- | -47.47 | -- |
| Orthocell Ltd | 6.06m | -7.42m | 81.64m | -- | -- | 35.68 | -- | 13.48 | -0.0369 | -0.0369 | 0.0301 | 0.0109 | 0.2182 | 1.50 | 27.68 | -- | -26.73 | -32.67 | -31.96 | -38.53 | 77.11 | 63.04 | -122.55 | -374.46 | 4.36 | -- | 0.2586 | -- | 215.24 | 51.53 | 31.39 | -- | 11.07 | -- |
| Argenica Therapeutics Ltd | 92.21k | -4.67m | 82.29m | -- | -- | 10.07 | -- | 892.40 | -0.0511 | -0.0511 | 0.001 | 0.0665 | 0.0109 | -- | 0.6384 | -- | -55.31 | -- | -69.00 | -- | -- | -- | -5,067.62 | -- | -- | -6,663.20 | 0.00 | -- | 2,340.00 | -- | -17.71 | -- | -- | -- |
| Next Science Ltd | 33.22m | -24.37m | 91.88m | -- | -- | 4.79 | -- | 2.77 | -0.1053 | -0.1053 | 0.1419 | 0.0658 | 1.46 | 7.47 | 8.33 | -- | -107.19 | -74.40 | -136.06 | -90.31 | 73.20 | 76.98 | -73.36 | -128.26 | 3.45 | -50.37 | 0.0698 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| Paradigm Biopharmaceuticals Ltd | 8.67m | -69.00m | 94.44m | -- | -- | 2.81 | -- | 10.90 | -0.2296 | -0.2296 | 0.0288 | 0.0962 | 0.1298 | -- | 2.25 | -- | -103.34 | -40.96 | -127.58 | -44.13 | 99.87 | -- | -796.30 | -466.85 | -- | -348.76 | 0.0085 | -- | 7.58 | 25.42 | -32.26 | -- | -- | -- |
| Vita Life Sciences Limited | 74.16m | 9.08m | 119.85m | 124.00 | 12.95 | 2.79 | 12.50 | 1.62 | 0.166 | 0.166 | 1.36 | 0.7695 | 1.33 | 2.34 | 7.35 | -- | 16.27 | 15.25 | 22.51 | 21.99 | 58.14 | 60.90 | 12.24 | 11.71 | 2.29 | -- | 0.0089 | 39.05 | 10.88 | 12.50 | 28.18 | 30.07 | 12.15 | 19.14 |
| Arovella Therapeutics Ltd | 139.02k | -10.23m | 120.77m | 14.00 | -- | 33.39 | -- | 868.71 | -0.0127 | -0.0127 | 0.0002 | 0.0034 | 0.0249 | -- | 15.15 | -- | -182.82 | -77.12 | -276.07 | -93.26 | 83.56 | 63.41 | -7,357.19 | -1,471.57 | -- | -- | 0.00 | -- | 45.47 | 0.3491 | -18.11 | -- | -68.72 | -- |
| Recce Pharmaceuticals Ltd | 6.81m | -11.32m | 121.35m | -- | -- | 226.89 | -- | 17.81 | -0.0637 | -0.0637 | 0.0385 | 0.0026 | 1.68 | -- | 52.84 | -- | -279.04 | -110.82 | -985.91 | -139.61 | -- | -- | -166.11 | -391.79 | -- | -24.07 | 0.2712 | -- | 39.53 | 27.79 | -19.03 | -- | -26.31 | -- |
| Proteomics International LaboratoriesLtd | 1.44m | -5.90m | 134.82m | -- | -- | 23.55 | -- | 93.30 | -0.0518 | -0.0518 | 0.0129 | 0.0437 | 0.1817 | -- | 11.13 | -- | -75.75 | -57.79 | -87.11 | -67.57 | -- | -- | -416.78 | -229.69 | -- | -283.47 | 0.0088 | -- | -14.64 | 4.12 | -24.20 | -- | 89.02 | -- |
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 31 Mar 2024 | 13.28m | 6.51% |
